Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.59 |
| ▸ | HTR1A | P08908 | 4/20 | 0.59 |
| ▸ | DRD1 | P21728 | 4/20 | 0.59 |
| ▸ | DRD4 | P21917 | 4/20 | 0.59 |
| ▸ | DRD5 | P21918 | 4/20 | 0.59 |
| ▸ | DRD3 | P35462 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8571166 | 0.84 | DRD2 (0.59) | DRD2HTR1ADRD1DRD5DRD3 | |
| SCHEMBL152587 | 0.83 | DRD2 (0.81) | DRD2HTR1ADRD1DRD4DRD5 | |
| SCHEMBL18937880 | 0.83 | CCR2 (0.47) | DRD2HTR1ADRD3 | |
| SCHEMBL4827157 | 0.82 | DRD2 (0.87) | DRD2HTR1ADRD1DRD4DRD5 | |
| SCHEMBL11939035 | 0.81 | DRD2 (0.83) | DRD2HTR1ADRD1DRD5DRD3 | |
| SCHEMBL24000014 | 0.81 | DRD2 (0.56) | DRD2HTR1ADRD1DRD4DRD5 | |
| SCHEMBL26911569 | 0.81 | DRD2 (0.57) | DRD2HTR1ADRD1DRD4DRD5 | |
| SCHEMBL28279156 | 0.80 | DRD2 (0.59) | DRD2DRD4 | |
| SCHEMBL256658 | 0.79 | DRD2 (0.82) | DRD2HTR1ADRD1DRD4DRD5 | |
| SCHEMBL9970928 | 0.79 | DRD2 (0.58) | DRD2HTR1ADRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391731-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | LIANGJIANG MEDICINE CO., LTD. (CN) | 2023-12-07 | — | — | US | disclosed |
| EP-4232437-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | Liangjiang Medicine Co., Ltd. (CN) | 2023-08-30 | — | — | EP | disclosed |
| CN-116529252-A | Prodrugs for sustained release of therapeutic agents and uses thereof | 重庆两江药物研发中心有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2022083679-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | LIANGJIANG MEDICINE CO., LTD. (CN) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022083679-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | LIANGJIANG MEDICINE CO., LTD. (CN) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391731-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | GRPR, SLC2A8, HPGDS | DRD2 4620/4885HTR1A 2186/4885DRD1 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.